PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 73 news outlets
blogs: 4 blogs
policy: 1 policy source
twitter: 311 X users
patent: 31 patents
facebook: 7 Facebook pages

wikipedia: 1 Wikipedia page
googleplus: 1 Google+ user
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 952 Mendeley

So far, Altmetric has seen 94 news stories from 73 outlets.

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

AJMC, 13 Jun 2025

Cemiplimab (Libtayo; Regeneron) showed efficacy in high-risk patients with cutaneous squamous cell carcinoma (CSCC) and in the…

Checkpoint inhibitor shows promise in advanced squamous-cell carcinoma

Pediatric News , 28 Aug 2024

FROM NEW ENGLAND JOURNAL OF MEDICINE An immune checkpoint inhibitor that targets the PD-1 receptor has shown “robust” efficacy…

Years of Progressing Facial Numbness and Deteriorating Vision Drives Diagnosis

MedPage Today, 02 Nov 2023

Case Studies > Neurology Suspect perineural recurrence of cutaneous squamous cell carcinoma, experts urge by Kate Kneisel…

Replimune: A Sell Ahead Of Cutaneous Squamous Cell Carcinoma Data

Seeking Alpha, 09 Mar 2023

Follow Summary Replimune develops oncolytic immunotherapies for cancer, with RP1 (vusolimogene oderparepvec) being their lead…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 90 additional news stories.